PSMA Targeted Therapy VL

Theranostics - Taking Over Prostate Cancer Care? - Phillip H. Kuo

Details
In this LUGPA CME presentation, Dr Phillip Kuo presents theranostics and its role in prostate cancer treatment. He provides a brief introduction into theranostics, a focus on PSMA, highlighting some select theranostic trials, then delves into a broader vision of what theranostics can mean, particularly to the nuclear medicine committee and PSMA. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of...

Ongoing Clinical Trials Evaluating The Efficacy of Targeted Radioligand Therapy - Shahneen Sandhu

Details
Alicia Morgans and Shahneen Sandhu discuss the advancements in targeted radioligand therapy for prostate cancer. Dr. Sandhu emphasizes the pioneering work done in Germany and her team's contributions in running the first prospective study on lutetium PSMA. Their research reveals significant PSA response rates and quality of life improvements in patients. The conversation also explores the importan...

The Use of Imaging for Patient Selection for PSMA Directed Therapies – Jeremie Calais

Details
Alicia Morgans speaks with Jeremie Calais about the evolving landscape of theranostic and imaging modalities in prostate cancer. The discussion primarily focuses on the role of PSMA PET imaging in patient selection for PSMA-directed therapies like lutetium PSMA. Dr. Calais elaborates on the criteria used in the VISION trial and the complexities surrounding the necessity of targeted imaging for tar...

PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris

Details
Alicia Morgans and Michael Morris, discuss the PSMAfore trial in progress. At the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial which examines the role of [177Lu]Lu-PSMA-617 in taxane-naïve patients with mCRPC. Dr. Morris reviews the radiographic progression-free survival (rPFS) data from the VISION trial and the complementary dat...

Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor

Details
Alicia Morgans and Oliver Sartor discuss additional data from the VISION trial that was recently presented at ESMO 2021. Dr. Sartor discusses the health-related quality of life findings from the VISON specifically pain and symptomatic skeletal events. Dr. Sartor offers the background on the VISION trial, while also describing the patient cohorts. Dr. Sartor discusses how the trial patients randomi...

The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris

Details
Alicia Morgans, MD, MPH, is joined by Michael Morris, MD, to discuss the phase III VISION trial results and the practice-changing implications when lutetium-177-PSMA-617 is FDA approved. The VISION trial evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined standard of care with...

Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu

Details
Phillip Koo and Evan Yu, discuss the phenotypic expression of PSMA. Phenotypic precision medicine guides physicians in looking at the molecular characteristics of a tumor to identify the optimal personalized treatment for the patient. Drs. Yu and Koo discuss the use of PSMA-PET/CT imaging that may fill the critical gaps in prostate cancer staging and as a biomarker for metabolic concordance or res...

Transforming The Standard of Care for Men With Advanced-Stage PSMA-Positive mCRPC, Published Results from the Phase III VISION Trial - Oliver Sartor

Details
Oliver Sartor, MD, joins Charles Ryan, MD in a conversation about the New England Journal of Medicine publication "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer" known as the VISION trial. The VISION Trial is an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with a...

PSMAddition, the Integration of Lutetium-177 With the Standard of Care Therapy in Metastatic Castrate-Sensitive Prostate Cancer Patients – Scott Tagawa & Oliver Sartor

Details
In this conversation, Scott Tagawa and Oliver Sartor join Charles Ryan in a discussion on the PSMAddition clinical trial that integrates lutetium-177 with standard-of-care therapy in metastatic castration-sensitive prostate cancer (mCSPC). The trial aims to determine the efficacy and safety of lutetium-177 administered earlier in the disease course. They believe that using lutetium-177 upfront wil...

The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor

Details
Oliver Sartor, MD, the CO-PI on the VISION Trial joins Alicia Morgans, MD, MPH in a conversation on the practice-changing VISION Trial results presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. 177Lu-PSMA-617 is a targeted radioligand therapy that delivers ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment. The VISION study was an int...